NCT00856492
Clinical Trial Information
Trial Number: NCT00856492 (ClinicalTrials.gov)
Disease Type:
- Breast Neoplasm - Breast Cancer (Invasive)
Trial Title:
"A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A)and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy For Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer"
Study ID:
S0800
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®